Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer
Conditions
Interventions
CG200745 PPA
Gemcitabine
+1 more
Locations
1
South Korea
Yonsei University Health System
Seoul, South Korea
Start Date
March 1, 2016
Primary Completion Date
August 1, 2019
Completion Date
August 1, 2019
Last Updated
June 17, 2019
NCT06885697
NCT07139236
NCT07035587
NCT06953193
NCT05218889
NCT06538623
Lead Sponsor
CrystalGenomics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions